JOURNAL ARTICLE

Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic.

  • Published In: Bloomberg.com, 2023. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Muller, Madison 3 of 3

Abstract

In a statement, the company said the drug would be sold at a slight premium to the price of the diabetes version of the same medication, sold as Mounjaro. (Bloomberg) -- Eli Lilly & Co.'s diabetes drug tirzepatide gained US approval for treating patients with obesity under a new name, Zepbound, unlocking blockbuster sales potential in a market that's expected to hit $100 billion by 2030. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2023/11, pN.PAG
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2023
  • Accession Number:173490149
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.